Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II study of sunitinib (SU011248) in patients with small cell lung cancer who are either chemo-naive (extensive disease) or have a "sensitive" relapse.

Trial Profile

Phase II study of sunitinib (SU011248) in patients with small cell lung cancer who are either chemo-naive (extensive disease) or have a "sensitive" relapse.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 02 Aug 2018

At a glance

  • Drugs Sunitinib (Primary)
  • Indications Small cell lung cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 12 Dec 2015 Results (n=9), published in the European Journal of Cancer.
    • 14 Jul 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 18 Aug 2009 Additional trial identifier NCT00953459, CDR0000639063, EU-20910 identified and inclusion and exclusion criteria amended as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top